The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 245-252

  Jung, Samil ^a   Yi, Lisha ^a   Jeong, Dongjun ^b   Kim, Jinsun ^a   An, Sungwhan ^c   Oh, Tae Jeong ^c   Kim, Chang Hwan ^b   Kim, Chang Jin ^b   Yang, Young ^a   Kim, Keun Il ^a   Lim, Jong Seok ^a   Lee, Myeong So ^a  

^a Sookmyung Women's University   (South Korea)

^b Soonchunhyang University   (South Korea)

^c Genomictree Inc   (South Korea)

Author keywords

ADCYAP1; Cervical cancer; Epigenetic gene regulation; Methylation biomarker

Indexed keywords

ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 1; ADENYLATE CYCLASE ACTIVATOR; BIOLOGICAL MARKER; POLYPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CARCINOGENESIS; CARCINOMA CELL; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; DNA TRANSCRIPTION; EARLY DIAGNOSIS; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

CPG ISLANDS; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 78650751448     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001067     Document Type: Article

References (27)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Erratum: estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 870-873, 1999.
2. Durst M, Glitz D, Schneider A and Zur HH: Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 189: 132-140, 1992.
3. Bosch FX, Manos MM, Munoz N, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87: 796-802, 1995.
4. Zur HH: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
5. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999.
6. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 262: 931-934, 1989.
7. Agorastos T, Miliaras D, Lambropoulos AF, et al: Detection and typing of human papillomavirus DNA in uterine cervices with coexistent grade I and grade III intraepithelial neoplasia: biologic progression or independent lesions. Eur J Obstet Gynecol Reprod Biol 121: 99-103, 2005.
8. Asakawa S, Tsunematsu K, Takayanagi A, et al: The genomic structure and promoter region of the human parkin gene. Biochem Biophys Res Commun 286: 863-868, 2001.
9. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266, 2003.
10. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer, a mechanism for early oncogenic pathway addiction. Nat Rev Cancer 6: 107-116, 2006.
11. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
12. Costello JF, Fruhwald MC, Smiraglia DJ, et al: Aberrant CpGisland methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132-138, 2000.
13. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
14. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 4: 988-983, 2004.
15. Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231, 2005. (Pubitemid 40314953)
16. Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463, 2004.
17. Jones PA and Buckley JD: The role of DNA methylation in cancer. Adv Cancer Res 54: 1-23, 1990.
18. Wolman SR, Heppner GH and Wolman E: New directions in breast cancer research. FASEB J 11: 535-543, 1997.
19. Isobe K, Kaneko M, Kaneko S, et al: Expression of mRNAs for PACAP and its receptor in human neuroblastomas and their relationship to catecholamine synthesis. Regul Pept 123: 29-32, 2004.
20. Garcia-Fernandez MO, Bodega G, Ruiz-Villaespesa A, Cortes J, Prieto JC and Carmena MJ: PACAP expression and distribution in human breast cancer and healthy tissue. Cancer Lett 205: 189-195, 2004.
21. Monaghan TK, Pou C, MacKenzie CJ, Plevin R and Lutz EM: Neurotrophic actions of PACAP-38 and LIF on human neuroblastoma SH-SY5Y cells. J Mol Neurosci 36: 45-56, 2008.
22. Castorina A, Tiralongo A, Giunta S, Carnazza ML, Rasi G and D'Agata V: PACAP and VIP prevent apoptosis in schwannoma cells. Brain Res 1241: 29-35, 2008.
23. Germano PM, Lieu SN, Xue J, et al: PACAP induces signaling and stimulation of 5-hydroxytryptamine release and growth in neuroendocrine tumor cells. J Mol Neurosci 39: 391-401, 2009.
24. Li M, Cortez S, Nakamachi T, Batuman V and Arimura A: Pituitary adenylate cyclase-activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res 66: 8796-8803, 2006.
25. Hayez N, Harfi I, Lema-Kisoka R, Svoboda M, Corazza F and Sariban E: The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells. J Neuroimmunol 149: 167-181, 2004.
26. Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431, 2002.
27. Garcia-Fernandez MO, Bodega G, Solano RM, et al: Expression and distribution of pituitary adenylate cyclase-activating peptide in human prostate and prostate cancer tissues. Regul Pept 110: 9-15, 2002.